Efficacy and safety of glucagon-like-peptide-1 receptor agonists on body weight and cardiometabolic parameters in individuals with obesity and without diabetes: A systematic review and meta-analysis
This triple-action mechanism distinguishes it from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist)
During audits or inspections, companies must demonstrate that these consumables meet quality standards and do not present a contamination risk
None of these drugs work as well as semaglutide or tirzepatide, experts say, but they may help with weight loss maintenance
doi:10.1111/bcp.12777 Simental-Menda LE, Snchez-Garca A, Linden-Torres E, Simental-Menda M
This medication represents a different approach to managing weight, supported by comprehensive care